Clinical trial · Observational
Transarterial Chemoembolization Plus Hypofractionnated Radiotherapy vs. Surgery in Locally Advanced Hepatocellular Carcinoma: an IPTW Comparison
NCT04823715CI-TRIAL-00050994TACE-hypoRTcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with non-metastatic unresectable hepatocellular carcinoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-metastatic Hepatocellular Carcinoma | Liver Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Surgical resection | Procedure | — | UNRESOLVED |
| TACE + hypofractionated EBRT | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- TACE- hypofractionated radiation therapy
- description
- Patients will receive one course of transarterial chemoembolization followed 1 to 4 weeks later by hypofractionated radiation therapy up to a total dose of 45 to 60 Gy, 3 Gy per fraction, 5 fractions per week, for an overall treatment time of 3 to 4 weeks.
- interventionNames
- Other: TACE + hypofractionated EBRT
- label
- Surgical resection
- description
- Surgical resection by open-laparotomy or laparoscopy of hepatocellular carcinoma
- interventionNames
- Procedure: Surgical resection
Primary outcomes (1)
- measure
- Disease-free survival of the patient after start of treatment
- timeFrame
- Within 10 years after the treatment (surgical resection or TACE)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years of age * ECOG 0-2 * Histologically proven hepatocellular carcinoma or proven according to radiological and biochemical criteria (EASL-AASLD) in cirrhotic patients * Child-Pugh class A * Absence of truncular or lobar portal vein invasion, or suprahepatic vein invasion Exclusion Criteria: * Uncontrolled replication of hepatitis B virus * Transplanted liver * Previous abdominal irradiation * Previous treatment of HCC with systemic therapy, or with surgical resection in the 2 previous years * Metastatic illness
References
Publications (0)
Data not yet available
No reference posted for this study.